Resection leads to cure in selected patients with hepatocellular

Size: px
Start display at page:

Download "Resection leads to cure in selected patients with hepatocellular"

Transcription

1 Overview: Where Does Radiation Therapy Fit in the Spectrum of Liver Cancer Local-Regional Therapies? Laura A. Dawson, MD*, Experience with radiation therapy for the treatment of hepatocellular carcinoma (HCC) and liver metastases has increased rapidly in the past decade. This is principally because of advances in imaging and radiation techniques that can conform high doses to focal cancers and to a better understanding of how to avoid radiation-induced liver toxicity. Guidelines on how to use radiation therapy safely are becoming more clearly established, and reports of tumor control at 2 to 5 years show the potential for cure after radiation therapy for early-stage HCC and liver metastases. For both HCC and liver metastases, the best outcomes after radiation therapy are found in patients with fewer than 3 lesions that are <6 cm in size, with intact liver function and no extrahepatic metastases. There is a strong rationale for using radiation therapy in patients unsuitable for or with expected poor outcomes after standard local-regional therapies. These patients tend to have advanced tumors (large, multifocal, or invading vessels) and/or impaired liver function, reducing the chance of cure and increasing the chance of toxicity. In these patients, the benefits of radiation therapy over systemic therapy or best supportive therapy should be established in randomized trials. Semin Radiat Oncol 21: Elsevier Inc. All rights reserved. Resection leads to cure in selected patients with hepatocellular carcinoma (HCC) or liver metastases. Unfortunately, the minority of patients are suitable for resection, either because of medical contraindications, excessive burden of hepatic disease, or insufficient liver functional reserve. Nonsurgical local and hepatic directed therapies have a role to play in these patients, but these interventions have limitations, and there is a need for improved therapies. Radiation therapy has a well-defined role in many malignancies in which organ (functional) preservation is desirable (eg, head and neck cancer, esophageal cancer, anal canal cancer, and breast cancer). Given that hepatic function is required to sustain life, it is surprising that radiation therapy does not yet have an established role in hepatic malignancies. This is partially because of the incorrect perception of inevitable liver toxicity after radiation therapy, technical challenges in delivering focused radiation therapy to the liver, *Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada. Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. Address reprint requests to Laura A. Dawson, MD, Radiation Medicine Program, Princess Margaret Hospital, University Health Network, 610 University Ave, Toronto, Ontario, Canada M5G 2M9. Laura. dawson@rmp.uhn.on.ca and a general lack of training in hepatobiliary malignancies in most radiation oncology residency programs. The tolerance of the liver to radiation therapy is better understood now than 20 years ago, at least for classic radiation-induced liver disease as described in the article by Kavanagh et al in this issue (see pages ). Advances in imaging, radiation planning, motion management, and image guidance at the time of radiation delivery make safe delivery of ablative doses of radiation therapy to focal liver tumors possible, as described in the article by Brock in this issue (see pages ). However, despite these advances, the doses that can be delivered to liver tumors, especially those unsuitable for other local-regional therapies, are often limited by the tolerance of the liver or adjacent luminal gastrointestinal tissues. A variety of radiation strategies have been developed with the goal of escalating the dose to liver tumors while maintaining low doses to normal tissues, especially the hepatic parenchyma. All radiation therapy strategies have been shown to be most safe and effective in patients with intact liver function and early-stage liver cancers. The potential for radiation sensitizers to improve the therapeutic ratio is described in the article by Seong et al in this issue (see pages ). In this overview, the potential of radiation therapy to improve outcomes in patients with HCC and liver metastases, relative to the already large spectrum of local-regional therapies available, is discussed /11/$-see front matter 2011 Elsevier Inc. All rights reserved. doi: /j.semradonc

2 242 L.A. Dawson HCC HCC is the third most common cause of cancer death globally, with an estimated 564,000 new cases annually. 1 Although HCC is less common in North America, the incidence has increased from 1.4 to 2.4 per 100,000 over the past 2 decades, and it is expected to continue to rise in parallel with the increasing incidence of hepatitis C. 2 Liver and biliary cancers are the most rapidly increasing cause of cancer death in the United States, with a 30% increase in death rate from 1991 to Cirrhosis from alcohol, viral hepatitis, autoimmune hepatitis, hemochromatosis, or nonalcoholic steatohepatitis (NASH) increases the risk of HCC developing. Patients with hepatitis C cirrhosis have a 5% to 20% 5-year cumulative incidence of HCC, and even in the absence of cirrhosis, hepatitis B infection is associated with a 15% risk of HCC. Many patients with cirrhosis have impaired liver function, and the degree of impairment impacts HCC prognosis and treatment options. The most commonly used measure of liver function is the Child-Pugh classification, which is based on the presence or absence of ascites and encephalopathy as well as bilirubin, albumin, and international normalized ratio (INR) levels. Survival is best in Child-Pugh class A and worst in Child-Pugh class C even in the absence of HCC. Given the importance of liver function as a prognostic factor and for treatment decision making, liver function is included in most staging and classification systems for HCC, such as the widely used Barcelona Clinic Liver Cancer (BCLC) (Fig. 1). 4,5 A weakness of the BCLC system is that BCLC advanced stage (C) includes patients with vascular invasion, lymph node involvement, or metastases. Prognosis varies considerably in these patients, and local therapies may be an option in focal HCC with vascular invasion but not in patients with diffuse extrahepatic metastases. The great majority of HCC patients die of tumor progression within the liver. Improved hepatic-directed therapies, including radiation therapy, have the potential to improve hepatic control, overall survival, and quality of life in HCC patients. Outcomes After Standard Therapies in HCC Cure from a variety of therapies is most likely in early-stage HCC, comprising 30% of the total HCC population. 4 Another 20% of HCC patients present in terminal stage in which palliative treatment is recommended. The remaining 50% of Where RT fits Unsuitable for resection, transplant or RF Definitive RT RT as bridge to transplant Unsuitable/refractory to TACE Definitive RT Symptomatic Low dose RT Portal invasion Definitive RT & sorafenib Randomized trials needed to demonstrate benefit Figure 1 BCLC classification for HCC including estimated incidence and accepted therapeutic options. Potential roles for RT are shown in the blue boxes in the bottom rows. An opportunity for randomized trials of radiation therapy is indicated by diamonds. For portal invasion, the optimal timing of radiation therapy and sorafenib is unknown, and radiation therapy and concurrent sorafenib is only recommended on a clinical trial. PST, performance status based on Eastern Cooperative Oncology Group score; N, nodal stage; M, metastases stage; CLD, cadaver liver transplantation; LDLT, living donor liver transplantation; RF, radiofrequency ablation; PEI, percutaneous ethanol injection; TACE, transarterial chemoembolization. (Modified with permission. 5 )

3 Radiation therapy and liver cancer 243 patients have incurable locally advanced disease or metastatic disease, possibly suitable for regional or systemic therapies, as shown in Figure 1. Liver transplantation is argued to be the ultimate therapy for HCC, especially in the setting of severe cirrhosis (Child-Pugh B or C) because both the cancer and the underlying liver dysfunction are simultaneously treated. The most widely accepted selection criteria for transplantation are the Milan criteria defined as a single tumor 5 cm or less or up to 3 tumors 3 cm or less with no extrahepatic spread or macrovascular involvement. When such criteria are followed, transplantation is associated with a 5-year overall survival of approximately 70%, and the recurrence rate is 15%. Unfortunately, there is a substantial wait time for transplantation because of a limited availability of donors, so many patients drop off the waitlist because of progression of HCC beyond the Milan criteria. Bridging therapies for patients on the waitlist may increase the percentage of patients who are transplanted. For patients with a solitary HCC without vascular invasion, with Child-Pugh A liver function, and no portal hypertension, partial liver resection is a treatment option. Operative mortality is low (1%-3%), and 5-year survival rates are approximately 50%. Mortality risks are higher (3%-13%) in the presence of cirrhosis. Unfortunately, recurrences and/or new foci of HCC occur in up to 70% of patients after resection. For patients with unresectable HCC, radiofrequency ablation (RFA) or other ablative approaches (ie, cryotherapy and microwave) are associated with a local control rate of 90% or higher in lesions 3 cm, away from large vessels. Larger lesions are more likely to recur after RFA. In a randomized trial of 180 patients with a solitary HCC 5 cm, survival was the same in patients treated with RFA versus resection. 13 Lesions near the dome of the liver are difficult to target with RFA effectively, and lesions near large vessels are not adequately heated because of heat sink from the adjacent vasculature; alternative local therapies would be beneficial in these situations. For patients with large or multifocal tumors, regional and systemic therapies are available. Hepatic tumors derive 80% of their blood supply from the hepatic artery, whereas the adjacent liver parenchyma is supplied by the portal vein. Thus, transarterial chemoembolization (TACE) or radioembolization, as described by Memon et al in this issue (see pages ), can target HCC with specificity via hepatic arterial delivery. TACE has been shown in randomized trials to improve survival duration compared with symptomatic therapy alone in patients without macrovascular involvement. 14,15 In tumors larger than 10 cm, morbidity of TACE is increased and efficacy is reduced. 16 Sorafenib, an oral multikinase inhibitor, improves survival in HCC patients unsuitable for any of the previously described therapies. In the SHARP (Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol) trial, median survival with sorafenib was improved from 7.9 to 10.7 months (P.001), 17 whereas in the Asia-Pacific trial, median survival was improved from 4.2 to 6.5 months (P.014). 18 Outcomes after standard therapies in HCC are summarized in Table 1. Overall, there is a strong need for more effective safe therapies. Table 1 Outcome Estimates for HCC (Child-Pugh A) Survival, 5 Years (%) Liver Metastases Hepatic Recurrence (%) Transplant Resection RFA (local recurrence) TACE <2 (31-63 at, 2 y) 100 sorafenib The liver is a frequent site of metastases for a variety of malignancies, including colorectal carcinoma, breast carcinoma, melanoma, and neuroendocrine tumors. A substantial proportion of these patients die of hepatic confined metastases. Although most patients with liver metastases have occult diffuse micrometastases making them incurable despite any liver-directed therapy, a proportion have oligometastases, meaning that the radiographically detected metastases are the only site of disease and that local control of the metastases may improve overall survival. 6 Although the concept of oligo metastases has not changed, the ability to better identify patients with true oligo metastases is increasing as staging investigations improve. Approximately 50% of patients with colorectal carcinoma develop liver metastases over the course of their lifetime. Five-year survival for metastatic colorectal carcinoma has increased over the past few decades, caused largely by advances in systemic therapy 3 and the wider use of resection or ablation of liver metastases. With chemotherapy alone, the 5-year survival for patients with unresectable colorectal liver metastases is 2%. Evidence for the use of local therapy for liver metastases is strongest in colorectal carcinoma, in which 5-year survival rates range from 33% to 58% after the resection of liver metastases. 7-9 For noncolorectal liver metastases, there is a less clear role of resection although long-term survivors have been reported after the resection of liver metastases from breast cancer, 10 sarcoma, 11 cutaneous or uveal melanoma, 12 and gynecologic malignancies. Patients with liver-confined metastases from colorectal carcinoma and other selected tumor sites, who have medical contraindications to resection or unresectable metastases, may be suitable for nonsurgical ablative therapies, such as radiation therapy, that may improve outcomes over systemic therapy alone. Outcomes After Standard Therapies in Liver Metastases Outcomes after resection for liver metastases from colorectal carcinoma have improved over time, from 30% to 40% to 50% to 58% for 5-year survival in more recent series. 7-9 In parallel, the patient selection for liver resection is expanding. Fong et al 7 reported the following adverse prognostic factors after liver resection for colorectal carcinoma metastases: the number of tumors removed ( 1), the size of the tumors removed ( 5 cm), the preoperative carcinoembryonic antigen level (greater or less than 200 ng/ml), the extent of

4 244 L.A. Dawson Table 2 Outcome Estimates for Colorectal Liver Metastases 5-Year Survival (%) Local Recurrence (%) Hepatic Recurrence (%) Mortality (%) Resection RFA <1 Systemic chemotherapy resection (less than or greater than a lobectomy), the resection margin (negative or positive), and the presence of extrahepatic disease. 7 Now, the decision to resect is not limited by the size or number of metastases but primarily by the ability to preserve a minimum functional liver remnant. Chemotherapy can be used in an effort to convert unresectable metastases to resectable, and outcomes in patients treated with surgery are better than historic controls treated with chemotherapy alone. Because liver regeneration occurs after resection, repeat or staged resections are possible in colorectal carcinoma liver metastases. Post-resection morbidity and mortality rates are lower in metastases compared with HCC, ranging from 20% to 45% and 1% to 3%, respectively. 7,8 Resection is sometimes used together with RFA in multilobar metastases unsuitable for extensive resections. RFA on its own is an option for small unresectable liver metastases distal to large vessels. Liver recurrence rates tend to be higher after RFA compared with resection, ranging from 12% to 57%. 19 Five-year survival after RFA ranges from 17% to 55% (Table 2). 8 With the exception of surgery for colorectal liver metastases, a challenge for the oncology community is to try to prove the benefits of local therapy for oligometastases over systemic therapy alone. Bias exists in single-institution and retrospective series showing the odd long-term survivors, so prospective trials are warranted. Types of Radiation Therapy A variety of techniques may be used to deliver radiation therapy to liver cancers, with treatment goals ranging from palliation to cure. Details of palliative, conformal, and stereotactic body radiation therapy for the treatment of liver metastases and HCC are described by Schefter et al (see pages ) and Feng et al (see pages ), respectively, in this issue. Also in this issue of Seminars, Ricke et al (see pages ) describe interstitial brachytherapy, and Memon et al review radioembolization for HCC and liver metastases. The best single-center outcomes seen in HCC patients treated with radiation therapy are in patients treated with charged particle therapy, as described by Krishnan et al (in this issue [see pages ]). The 5-year survival rates in 162 HCC patients with impaired liver function, treated with 72-Gy cobalt equivalent in 16 fractions, was 24%; for 50 patients with Child-Pugh A and isolated HCCs, 5-year survival was 54%, which is similar to surgical series. 20 In both liver metastases and HCC, local control of lesions 3 cm is very high (80%-100% at 1-2 years) after conformal or stereotactic radiation therapy, charged particle therapy, or percutaneous brachytherapy. Some of these patients have no evidence of disease more than 5 years after therapy, showing that cure may be possible. These are the minority of patients treated, and long-term survival is uncommon in most radiation therapy series, largely because of the inclusion of patients with more advanced disease and poor prognostic factors, increasing the probability of extrahepatic progression of disease. Comparisons of outcomes of radiation techniques to each other and to surgery, ablation, and regional therapies are hampered because of the large variability in selection criteria and prior and subsequent therapies. In general, reported local control and survival are better than those reported after systemic therapies but not as good as outcomes in (better prognosis) patients treated with surgery or RFA. All radiation techniques are dependent on state-of-the-art imaging to define the liver target volume, as described by in the article by Brock in this issue (see pages ). Quality assurance is also crucial; most techniques require sophisticated patient immobilization, motion management, and specialized training. All require collaboration with other members of the hepatobiliary team. A dose response has been shown for both HCC and liver metastases; however, the optimal dose and fractionation for HCC and metastases are not clearly defined. Even though high doses are desirable, hepatic and/or nonhepatic normal tissues often limit the maximal dose that can be safely delivered. Table 3 summarizes which radiation therapy techniques may be used in different situations, with more s indicating a stronger role (increased chance of tumor control and lower risks), and 0 indicating no role. When deciding which technique may be used in which situation, in addition to tumor and patient criteria, center availability, expertise and cost need to be considered. Most Appropriate Patients for Radiation Therapy The most appropriate patients to be referred for radiation therapy are those in whom radiation therapy can be delivered safely, with an expected benefit to the patient. These criteria do not necessarily overlap (ie, the technical ability to deliver high doses of radiation to focal liver cancers is different from the clinical indication for liver-directed therapy). Table 4 outlines factors to be considered in determining the safety of radiation therapy, and Table 5 outlines factors that are related to chance of patient benefit. These tables are not based on level 1 evidence, and they are meant to be used for guidance only.

5 Radiation therapy and liver cancer 245 Table 3 Eligibility Criteria for Different Radiation Techniques CRT SBRT Proton* Brachy Yttrium-90 <3 cm 3-6 cm 6-10 cm >10 cm Diffuse High bleeding risk 0 0 Child-Pugh B Vascular invasion Caudate lobe Target <1 cm from GI tissues *Proton, protons or any other charged particle therapy. GI tissues, luminal gastrointestinal tissues (eg, stomach, duodenum). Abbreviations: CRT, conformal radiation therapy; SBRT, stereotactic radiation therapy; Brachy, brachytherapy; Yttrium-90, hepatic arterial yttrium-90. The proximity of the liver target volume to luminal gastrointestinal tissues, such as the stomach, impacts the ability to deliver high doses safely, but the cutoff of what distance is safe is dependent on technical factors, such as motion management, image guidance used, and the dose gradient at the target-normal tissue interface. For example, it is possible to deliver ablative doses using most radiation techniques when the target is more than 2 cm from the stomach, but if the target is within 1 cm from the stomach wall, the dose that can be delivered safely to the target most often needs to be decreased to respect the stomach radiation tolerance. Of note, insertion of tissue expanders may help to move the stomach from the tumor in this situation. Because there are little long-term data suggesting radiation therapy may compete with surgery, the gold standard local therapy, radiation therapy should be used outside of a clinical trial only for unresectable tumors or medically inoperable patients. An ideal candidate for liver radiation therapy may be a patient with unresectable disease and all the best criteria from Tables 4 and 5. An example of such an ideal liver metastases candidate is a patient with an isolated unresectable 3-cm liver metastasis from colorectal cancer, adjacent to a large vessel, more than 2 cm from all luminal gastrointestinal tissues, who is medically unsuitable for surgery or systemic therapy. An example of an ideal HCC candidate is a patient with a focal recurrence post-tace, Child-Pugh A, in whom tumoricidal doses of radiation therapy are possible to Table 4 Factors to Consider in Determining the Safety of Radiation Therapy Liver function Child-Pugh A versus B versus C Planned residual functional liver >700 ml nontumor liver (vs <700 ml) Distribution of tumor(s) (focal versus diffuse) Number of tumors (<3 vs 3-5 vs >5) Liver dose volume constraints can be met Target proximity to luminal gastrointestinal tissues >2 cm from tumor (versus 1-2 cm versus <1 cm) Experience with specific radiation therapy technique deliver safely. In these situations, radiation therapy should be considered before the next line of systemic therapy because long-term control is likely after radiation therapy. In HCC, this population of patients suitable for focal irradiation extends from very early to intermediate BCLC stage as shown in Figure 1. The highest chance of tumor control after radiation therapy is in very early and early-stage HCC ( 3 cm); however, in intermediate stage HCC 3 to 6 cm in size, tumoricidal doses are often possible to deliver, and the chance of sustained local control is only slightly reduced. Radiation therapy should be considered early in these patients natural history. In intermediate-stage HCC with a lower chance of local control from radiation therapy (multifocal tumors, 10 cm, vascular invasion, or adjacent to luminal gastrointestinal tissues), the rationale for upfront radiation therapy is reduced. In these patients, radiation therapy may be used after TACE, which may reduce the bulk of HCC. For advanced-stage N0M0 focal nonbulky HCC with portal vein invasion, radiation therapy can lead to tumor thrombosis recanalization and sustained tumor control; in these patients, radiation therapy should be considered either before or early after progression or intolerance to sorafenib. Concurrent sorafenib and radiation therapy should only be delivered on clinical trials. Radiation therapy is not likely to improve Table 5 Factors to Consider in Determining Efficacy of Radiation Therapy Natural history (indolent vs rapidly progressive) Presence of extrahepatic disease (none vs possible vs definite) Risk of extrahepatic and occult hepatic metastases Tumor type (colorectal, breast, sarcoma, melanoma vs pancreatic, lung, duodenum) Biologic selection Refractory to 1 line of systemic therapy vs 1 or more Vascular invasion (portal vein branch vs main portal vein vs inferior vena cava) Tumoricidal dose deliverable Number of tumors (< 3 vs 3-5 vs >5) Size of tumors (<6 cm vs 6-10 cm vs >10 cm)

6 246 L.A. Dawson Table 6 Proposed Randomized Trials in HCC 1. Intermediate BCLC HCC: TACE vs TACE and radiation therapy 2. Advanced BCLC stage, N0M0 HCC: sorafenib vs sorafenib and radiation therapy 3. End-stage symptomatic BCLC HCC: best supportive care vs low-dose radiation therapy survival in patients with diffuse HCC or extrahepatic metastases. In end-stage HCC, low-dose radiation therapy may improve symptoms and provide palliative benefit. Ideally, randomized trials will be conducted to test the benefits of radiation therapy in these situations as outlined in Table 6. Randomized trials will be more difficult to conduct in liver metastases because of the multiple primary sites and variable natural history of patients with liver metastases as well as the wide range of changing systemic therapies for these patients. Conclusions A variety of radiation therapy strategies can be used safely across a spectrum of patients with liver metastases or HCC. Toxicity is increased in patients with advanced HCC and impaired liver function (Child-Pugh B or C). For both HCC and liver metastases, long-term local control and cure are most likely in patients with 3 or fewer tumors, 3 cm each, in the absence of extrahepatic disease. Radiation therapy may also help patients with 3 or more larger liver metastases, but the benefit is less as the tumor burden increases because of reduced tumor control probability and the increased risk of occult diffuse metastases. In intermediate- and advancedstage HCC, radiation therapy can delay the time to tumor progression and recanalize vascular thrombosis. In both HCC and liver metastases, there is a strong rationale for randomized trials of radiation therapy. References 1. Bosch FX, Ribes J, Diaz M, et al: Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127:S5-S16, Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics. CA Cancer J Clin 2005:74-108, Jemal A, Siegel R, Xu J, et al: Cancer statistics. CA Cancer J Clin 60: , Bruix J, Sherman M: Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology 42: , Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: , Hellman S, Oligometastases WRR. J Clin Oncol 13:8 10, Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230: , Lo SS, Moffat-Bruce SD, Dawson LA, et al: The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 2011 [Epub ahead of print] 9. Wei AC, Greig PD, Grant D, et al: Survival after hepatic resection for colorectal metastases: A 10-year experience. Ann Surg Oncol 13: , Hoffmann K, Franz C, Hinz U, et al: Liver resection for multimodal treatment of breast cancer metastases: Identification of prognostic factors. Ann Surg Oncol 17: , Rehders A, Peiper M, Stoecklein NH, et al: Hepatic metastasectomy for soft-tissue sarcomas: Is it justified? World J Surg 33: , Mariani P, Piperno-Neumann S, Servois V, et al: Surgical management of liver metastases from uveal melanoma: 16 years experience at the Institut Curie. Eur J Surg Oncol 35: , Hong SN, Sy L, Choi MS, et al: Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 39: , Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: , Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359: , Thornton RH, Covey A, Petre EN, et al: A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. Cancer 115: , Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: , Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, Bleicher RJ, Allegra DP, Nora DT, et al: Radiofrequency ablation in 447 complex unresectable liver tumors: Lessons learned. Ann Surg Oncol 10:52-58, Chiba T, Tokuuye K, Matsuzaki Y, et al: Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients. Clin Cancer Res 11: , 2005

Radiation Therapy for Liver Malignancies

Radiation Therapy for Liver Malignancies Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies

More information

Hepatocellular Carcinoma: Diagnosis and Management

Hepatocellular Carcinoma: Diagnosis and Management Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm

More information

Management of HepatoCellular Carcinoma

Management of HepatoCellular Carcinoma 9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma

More information

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

News Release. Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012

News Release. Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012 News Release Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012 Contact: Michelle Kirkwood 703-286-1600 michellek@astro.org Concurrent use of sorafenib and stereotactic body radiotherapy for advanced

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

Liver resection for HCC

Liver resection for HCC 8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

Proton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center

Proton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center Proton Beam Therapy for Hepatocellular Carcinoma Li Jiamin, MD Wanjie Proton Therapy Center 1 1 Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide It is the eighth most common neoplasm

More information

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer

More information

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration

More information

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in

More information

Guidelines for SIRT in HCC An Evolution

Guidelines for SIRT in HCC An Evolution Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early

More information

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT

More information

Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.

Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V. Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V. Hepatocellular carcinoma (HCC), is a major health problem worldwide.

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

MANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011

MANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011 MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal

More information

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which

More information

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE

More information

The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page

The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed

More information

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer

More information

Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates

Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses

More information

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views

More information

Staging & Current treatment of HCC

Staging & Current treatment of HCC Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt

More information

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine

More information

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network

More information

Liver transplantation: Hepatocellular carcinoma

Liver transplantation: Hepatocellular carcinoma Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona

More information

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies

More information

HCC: Is it an oncological disease? - No

HCC: Is it an oncological disease? - No June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -

More information

Surgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London

Surgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,

More information

Hepatocellular Carcinoma: Transplantation, Resection or Ablation?

Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective

More information

SBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment

SBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment SBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment Nima Nabavizadeh, MD Assistant Professor Division Leader Hematologic Malignancies Co-division Leader Gastrointestinal

More information

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal

More information

Management of Stage IV Colorectal Cancer: Expanding the Horizon

Management of Stage IV Colorectal Cancer: Expanding the Horizon Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 114 Effective Health Care Program Local Therapies for Unresectable Primary Hepatocellular Carcinoma Executive Summary Introduction Background This comparative effectiveness

More information

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Cryosurgical Ablation of Primary or Metastatic Liver Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cryosurgical_ablation_of_primary_or_metastatic_liver_tumors

More information

PRIOR AUTHORIZATION Prior authorization is required for BlueCHiP for Medicare members and recommended for Commercial products.

PRIOR AUTHORIZATION Prior authorization is required for BlueCHiP for Medicare members and recommended for Commercial products. Medical Coverage Policy Radioembolization for Primary and Metastatic Tumors of the Liver EFFECTIVE DATE: 10 06 2009 POLICY LAST UPDATED: 08 02 2016 OVERVIEW Radioembolization (RE), referred to as selective

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information

Jose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma

Jose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre Evolution of liver resection Better understanding

More information

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue

More information

Paul Martin MD FACG. University of Miami

Paul Martin MD FACG. University of Miami Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28

More information

SIRT for Intermediate and Advanced HCC

SIRT for Intermediate and Advanced HCC Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro

More information

Liver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties

Liver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties Patient Education Treatment options This handout describes different kinds of tumors that form in the liver and how they are treated. About the Liver Your liver is the largest organ in your abdomen. It

More information

Liver Cancer: Diagnosis and Treatment Options

Liver Cancer: Diagnosis and Treatment Options Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver

More information

TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD

TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD UNIVERSITY OF PRETORIA STEVE BIKO ACADEMIC HOSPITAL SOUTH AFRICA TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD 1 INTRODUCTION Hepatic

More information

EASL-EORTC Guidelines

EASL-EORTC Guidelines Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according

More information

Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College

More information

Interventional Radiologic Treatment of Hepatocellular Carcinoma

Interventional Radiologic Treatment of Hepatocellular Carcinoma Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular

More information

Management of Colorectal Liver Metastases

Management of Colorectal Liver Metastases Management of Colorectal Liver Metastases MM Bernon, JEJ Krige HPB Surgical Unit, Groote Schuur Hospital Department of Surgery, University of Cape Town 50% of patients with colorectal cancer develop liver

More information

Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010

Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate

More information

Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma

Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma International Course on THERANOSTICS and MOLECULAR RADIOTHERAPY Brussels, 4 october 2017 Vincent Donckier

More information

Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology

Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT

More information

Where are we with radiotherapy for biliary tract cancers?

Where are we with radiotherapy for biliary tract cancers? Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute

More information

100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days

100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days 100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,

More information

NCCN Guidelines Update: Locoregional Treatment Approaches for Hepatocellular Carcinoma. Memorial Sloan Kettering Cancer Center. Anne M Covey, MD, FSIR

NCCN Guidelines Update: Locoregional Treatment Approaches for Hepatocellular Carcinoma. Memorial Sloan Kettering Cancer Center. Anne M Covey, MD, FSIR NCCN Guidelines Update: Locoregional Treatment Approaches for Hepatocellular Carcinoma Daniel T. Chang, MD Stanford Cancer Institute Anne Covey, MD Memorial Sloan Kettering Cancer Center Locoregional Therapy

More information

Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis

Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol

More information

Transcatheter hepatic arterial chemoembolization may be considered medically necessary to

Transcatheter hepatic arterial chemoembolization may be considered medically necessary to Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Hepatocellular carcinoma Transcatheter hepatic arterial chemoembolization

More information

Radiotherapy What are our options and what is on the horizon. Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology

Radiotherapy What are our options and what is on the horizon. Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology Radiotherapy What are our options and what is on the horizon Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology Outline Advances in radiotherapy technique Oligo - disease Advancements

More information

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies. Original Policy Date

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies. Original Policy Date MP 8.01.09 Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date

More information

Liver Cancer And Tumours

Liver Cancer And Tumours Liver Cancer And Tumours What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood from all parts of the body, cancer cells from elsewhere can

More information

Disclosures. Fees for Non CME/CE services received. agents: Bayer Healthcare. CT guided HDR Brachytherapy in Oligometastases

Disclosures. Fees for Non CME/CE services received. agents: Bayer Healthcare. CT guided HDR Brachytherapy in Oligometastases CT guided HDR Brachytherapy in Oligometastases Jens Ricke Radiology and Nuclear medicine University of Magdeburg Disclosures Fees for Non CME/CE services received directlyfrom a commercial interest or

More information

Workup of a Solid Liver Lesion

Workup of a Solid Liver Lesion Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated

More information

Colon Cancer Liver Metastases: Liver-Directed Therapy

Colon Cancer Liver Metastases: Liver-Directed Therapy Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014

More information

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Radiofrequency Ablation of Primary or Metastatic Liver Tumors Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)

More information

The role of Radiation Oncologist: Hi-tech treatments for liver metastases

The role of Radiation Oncologist: Hi-tech treatments for liver metastases The role of Radiation Oncologist: Hi-tech treatments for liver metastases Icro Meattini, MD Radiotherapy-Oncology Unit AOU Careggi Hospital Florence University, Italy Liver Metastases - Background The

More information

Hepatocellular carcinoma in Sri Lanka - where do we stand?

Hepatocellular carcinoma in Sri Lanka - where do we stand? SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA

UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the

More information

Disclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:

Disclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company

More information

Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan

Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be

More information

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY

More information

Liver Directed Therapy for Hepatocellular Carcinoma

Liver Directed Therapy for Hepatocellular Carcinoma Liver Directed Therapy for Hepatocellular Carcinoma Anil K Pillai MD, FRCR, Associate Professor, Department of Radiology UT Houston Health Science Center, Houston, TX, United States. Hepatocellular cancer

More information

In- and exclusion criteria

In- and exclusion criteria In- and exclusion criteria Kerstin Schütte Department of Gastroenterology, Hepatology and Infectious Diseases University of Magdeburg Overview: Study population Inclusion criteria I - General criteria

More information

Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases

Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora silentio» Malignant

More information

Il treatment plan nella terapia sistemica dell epatocarcinoma

Il treatment plan nella terapia sistemica dell epatocarcinoma Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione

More information

Management of Liver Metastasis from Colorectal Carcinoma. Aisha White, M.D. SUNY Downstate Division of Transplantation

Management of Liver Metastasis from Colorectal Carcinoma. Aisha White, M.D. SUNY Downstate Division of Transplantation Management of Liver Metastasis from Colorectal Carcinoma Aisha White, M.D. SUNY Downstate Division of Transplantation Management of Colorectal Liver Metastasis Epidemiology 25% of patients diagnosed

More information

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

Unmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim

Unmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC

More information

State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options

State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options Ioannis S. Hatzaras, MD, MPH, FACS Assistant Professor of Surgery Division of Surgical Oncology

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

Ablative Radiation Therapy For Inoperable Cholangiocarcinoma. Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology

Ablative Radiation Therapy For Inoperable Cholangiocarcinoma. Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology Ablative Radiation Therapy For Inoperable Cholangiocarcinoma Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology Facts about radiation treatment High doses (2x the

More information

Locoregional Therapy for Hepatoma

Locoregional Therapy for Hepatoma Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish

More information

Pancreatic Cancer and Radiation Therapy

Pancreatic Cancer and Radiation Therapy Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op

More information

Surgical resection for hepatocellular carcinoma (HCC)

Surgical resection for hepatocellular carcinoma (HCC) Surgical resection for hepatocellular carcinoma (HCC) Wojciech G Polak, MD, PhD, FEBS Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC, University Medical Center Rotterdam the

More information

Rob Glynne-Jones Mount Vernon Cancer Centre

Rob Glynne-Jones Mount Vernon Cancer Centre ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 Interventional radiology and stereotactic radiotherapy Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:

More information

Palliative radiotherapy in lung cancer

Palliative radiotherapy in lung cancer New concepts and insights regarding the role of radiation therapy in metastatic disease Umberto Ricardi University of Turin Department of Oncology Radiation Oncology Palliative radiotherapy in lung cancer

More information

蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )

蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip

More information

NAACCR Webinar Series 1

NAACCR Webinar Series 1 Collecting Cancer Data: Liver 2013 2014 NAACCR Webinar Series June 5, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

SECONDARIES: A PRELIMINARY REPORT

SECONDARIES: A PRELIMINARY REPORT HPB Surgery, 1990, Vol. 2, pp. 69-72 Reprints available directly from the publisher Photocopying permitted by license only 1990 Harwood Academic Publishers GmbH Printed in the United Kingdom CASE REPORTS

More information

Embolotherapy for Cholangiocarcinoma: 2016 Update

Embolotherapy for Cholangiocarcinoma: 2016 Update Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial

More information

Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?

Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:

More information

Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14

Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14 Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related

More information

Sorafenib for the treatment of advanced hepatocellular carcinoma

Sorafenib for the treatment of advanced hepatocellular carcinoma DOI: 10.3310/hta14suppl1/03 Health Technology Assessment 2010; Vol. 14: Suppl. 1 Sorafenib for the treatment of advanced hepatocellular carcinoma M Connock, 1 J Round, 2 S Bayliss, 1 S Tubeuf, 2 W Greenheld

More information

Index. C Cancer, Carcinoid syndrome, 413. D DCIS. See Ductal carcinoma in situ (DCIS) DEB-TACE. See Drug eluting beads-tace (DEB-TACE)

Index. C Cancer, Carcinoid syndrome, 413. D DCIS. See Ductal carcinoma in situ (DCIS) DEB-TACE. See Drug eluting beads-tace (DEB-TACE) Index A Ablation, 179 199, 843 853 devices, 179, 199 liver tumors, 527 techniques, 516 Ablative radiation therapy, 456 Accelerated partial breast, 894, 896 898 Adaptive radiation therapy, 586, 598, 602

More information

Advances in percutaneous ablation for hepatocellular carcinoma

Advances in percutaneous ablation for hepatocellular carcinoma Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France

More information

Hepatocellular carcinoma: from guidelines to individualized treatment

Hepatocellular carcinoma: from guidelines to individualized treatment AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal

More information